ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Steven M. Altschuler as independent Chairman to its Board of Directors. Dr Altschuler is a renowned biotech company…
– ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases with unmet clinical need – Series A led by 4BIO Capital, BGF, and UCB Ventures with participation…
SomaServe Ltd, a pioneer in nanomedicines for crossing biological barriers today announced that it has completed a highly successful, oversubscribed late seed funding of £2.1m. SomaServe has also secured further IP and global commercial rights to PolyNaut® platform technology (the…
Abcam and SomaServe announce comprehensive partnership to realise the potential of PolyNaut® ‘bionic’ nanoparticles for delivery to live cells. Commercialise novel cell delivery platform technology Develop novel delivery methods for research applications Revolutionise utility of live cell imaging to explore disease…